IMDX

Insight Molecular Diagnostics is a clinical-stage story dressed as a commercial company. FY2025 revenue was just $4.05M — up a headline-grabbing 115.6%, but off a base so small it's noise: revenue was actually higher in FY2021 ($2.20M) and the five-year track record ($2.20M→$958K→$1.50M→$1.88M→$4.05M) shows no durable trajectory. Against that, the company burned a -$50.2M net loss and -$22.2M of operating cash, with R&D alone ($15.9M) nearly 4x total revenue. Gross margin of 56.7% is respectable, but operating margin of -1,260% tells you the P&L is a research budget, not a business.

The balance sheet is the disqualifier. Stockholders' equity is negative -$31.5M against total liabilities of $57.2M, and the accumulated deficit has reached -$401M — the filing states $400.8M as of Dec 31, 2025. Management explicitly discloses an ASC 205-40 going-concern evaluation and warns it 'expects to continue to incur operating losses and negative operating cash flows for the foreseeable future.' With only $11.6M cash at year-end against a ~$22M annual burn, survival depends entirely on capital markets: the company raised $28.7M net in Feb 2025 and another $24.6M net in Feb 2026, and shares outstanding already grew 12.5% in a year. This is a serial-dilution machine, and management flatly cannot 'assure that adequate long-term financing will be available on favorable terms, if at all.'